
<div id="jpedal" style="overflow: hidden; position: relative; width: 893px; height: 1196px;">
<style type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position:absolute;
	white-space:nowrap;
	overflow:visible;
}
</style>
<style type="text/css" >

#t1_5{left:69px;top:103px;word-spacing:13px;}
#t2_5{left:326px;top:102px;}
#t3_5{left:346px;top:103px;word-spacing:13.4px;}
#t4_5{left:69px;top:121px;word-spacing:9px;}
#t5_5{left:69px;top:140px;word-spacing:19.1px;}
#t6_5{left:69px;top:158px;letter-spacing:0.1px;word-spacing:5.1px;}
#t7_5{left:285px;top:156px;}
#t8_5{left:87px;top:176px;word-spacing:2.2px;}
#t9_5{left:69px;top:195px;word-spacing:7.6px;}
#ta_5{left:69px;top:213px;letter-spacing:0.1px;word-spacing:1.4px;}
#tb_5{left:69px;top:231px;word-spacing:0.6px;}
#tc_5{left:69px;top:249px;word-spacing:0.9px;}
#td_5{left:69px;top:268px;word-spacing:6.5px;}
#te_5{left:69px;top:286px;letter-spacing:0.1px;word-spacing:22.7px;}
#tf_5{left:69px;top:304px;word-spacing:12.4px;}
#tg_5{left:69px;top:322px;letter-spacing:0.1px;word-spacing:12.2px;}
#th_5{left:69px;top:341px;word-spacing:32px;}
#ti_5{left:69px;top:359px;word-spacing:4px;}
#tj_5{left:69px;top:377px;word-spacing:21.3px;}
#tk_5{left:69px;top:395px;word-spacing:6.4px;}
#tl_5{left:69px;top:414px;word-spacing:7.5px;}
#tm_5{left:470px;top:103px;word-spacing:6.9px;}
#tn_5{left:470px;top:121px;word-spacing:1.7px;}
#to_5{left:470px;top:140px;word-spacing:5.3px;}
#tp_5{left:489px;top:158px;word-spacing:15.6px;}
#tq_5{left:470px;top:176px;word-spacing:3.1px;}
#tr_5{left:470px;top:195px;word-spacing:-0.1px;}
#ts_5{left:470px;top:213px;letter-spacing:0.1px;word-spacing:6.1px;}
#tt_5{left:470px;top:231px;word-spacing:2.1px;}
#tu_5{left:470px;top:249px;word-spacing:12px;}
#tv_5{left:470px;top:268px;word-spacing:7.4px;}
#tw_5{left:470px;top:286px;letter-spacing:0.1px;word-spacing:22.3px;}
#tx_5{left:470px;top:304px;word-spacing:4.2px;}
#ty_5{left:470px;top:322px;letter-spacing:0.1px;word-spacing:21.4px;}
#tz_5{left:470px;top:341px;word-spacing:3.6px;}
#t10_5{left:470px;top:359px;word-spacing:16.4px;}
#t11_5{left:470px;top:377px;word-spacing:11.7px;}
#t12_5{left:470px;top:395px;word-spacing:5.3px;}
#t13_5{left:470px;top:414px;word-spacing:5.2px;}
#t14_5{left:69px;top:493px;}
#t15_5{left:75px;top:523px;word-spacing:8px;}
#t16_5{left:89px;top:539px;word-spacing:15.3px;}
#t17_5{left:89px;top:554px;word-spacing:3.9px;}
#t18_5{left:257px;top:554px;}
#t19_5{left:274px;top:554px;}
#t1a_5{left:75px;top:579px;letter-spacing:-0.1px;word-spacing:13.2px;}
#t1b_5{left:89px;top:594px;word-spacing:10.2px;}
#t1c_5{left:89px;top:609px;word-spacing:4.9px;}
#t1d_5{left:89px;top:624px;word-spacing:0.3px;}
#t1e_5{left:89px;top:640px;word-spacing:3.8px;}
#t1f_5{left:187px;top:640px;}
#t1g_5{left:210px;top:640px;}
#t1h_5{left:75px;top:665px;letter-spacing:-0.1px;word-spacing:7.9px;}
#t1i_5{left:89px;top:680px;word-spacing:2px;}
#t1j_5{left:89px;top:695px;word-spacing:4px;}
#t1k_5{left:158px;top:695px;}
#t1l_5{left:175px;top:695px;}
#t1m_5{left:75px;top:720px;word-spacing:27.2px;}
#t1n_5{left:89px;top:735px;word-spacing:1.1px;}
#t1o_5{left:89px;top:751px;word-spacing:4.6px;}
#t1p_5{left:89px;top:766px;}
#t1q_5{left:117px;top:766px;}
#t1r_5{left:140px;top:766px;}
#t1s_5{left:75px;top:791px;letter-spacing:-0.1px;word-spacing:18px;}
#t1t_5{left:89px;top:806px;word-spacing:2.9px;}
#t1u_5{left:89px;top:821px;letter-spacing:-0.1px;word-spacing:4.1px;}
#t1v_5{left:225px;top:821px;}
#t1w_5{left:247px;top:821px;}
#t1x_5{left:75px;top:846px;letter-spacing:-0.1px;word-spacing:14.1px;}
#t1y_5{left:89px;top:862px;letter-spacing:-0.1px;word-spacing:16.2px;}
#t1z_5{left:89px;top:877px;word-spacing:0.3px;}
#t20_5{left:89px;top:892px;word-spacing:3.9px;}
#t21_5{left:149px;top:892px;}
#t22_5{left:172px;top:892px;}
#t23_5{left:75px;top:917px;letter-spacing:-0.1px;word-spacing:1.6px;}
#t24_5{left:89px;top:932px;word-spacing:14.6px;}
#t25_5{left:89px;top:947px;letter-spacing:-0.1px;word-spacing:4.2px;}
#t26_5{left:213px;top:947px;}
#t27_5{left:225px;top:947px;}
#t28_5{left:75px;top:972px;letter-spacing:-0.1px;word-spacing:11.4px;}
#t29_5{left:89px;top:988px;letter-spacing:-0.1px;word-spacing:3.4px;}
#t2a_5{left:89px;top:1003px;word-spacing:6px;}
#t2b_5{left:89px;top:1018px;word-spacing:3.8px;}
#t2c_5{left:167px;top:1018px;}
#t2d_5{left:184px;top:1018px;}
#t2e_5{left:75px;top:1043px;word-spacing:9.4px;}
#t2f_5{left:89px;top:1058px;word-spacing:9.5px;}
#t2g_5{left:89px;top:1074px;word-spacing:9px;}
#t2h_5{left:89px;top:1089px;letter-spacing:-0.1px;word-spacing:4px;}
#t2i_5{left:231px;top:1089px;}
#t2j_5{left:254px;top:1089px;}
#t2k_5{left:69px;top:1114px;letter-spacing:-0.1px;word-spacing:7.5px;}
#t2l_5{left:88px;top:1129px;word-spacing:5.8px;}
#t2m_5{left:353px;top:523px;word-spacing:6.4px;}
#t2n_5{left:353px;top:539px;word-spacing:0.5px;}
#t2o_5{left:353px;top:554px;word-spacing:4.1px;}
#t2p_5{left:482px;top:554px;}
#t2q_5{left:505px;top:554px;}
#t2r_5{left:333px;top:579px;letter-spacing:-0.1px;word-spacing:26.1px;}
#t2s_5{left:353px;top:595px;word-spacing:5.6px;}
#t2t_5{left:353px;top:610px;}
#t2u_5{left:394px;top:610px;}
#t2v_5{left:426px;top:610px;letter-spacing:-0.2px;}
#t2w_5{left:503px;top:610px;}
#t2x_5{left:546px;top:610px;}
#t2y_5{left:353px;top:625px;}
#t2z_5{left:376px;top:625px;}
#t30_5{left:333px;top:651px;word-spacing:13.1px;}
#t31_5{left:353px;top:666px;letter-spacing:-0.1px;word-spacing:18.4px;}
#t32_5{left:353px;top:681px;letter-spacing:-0.1px;word-spacing:4.1px;}
#t33_5{left:489px;top:681px;}
#t34_5{left:512px;top:681px;}
#t35_5{left:333px;top:707px;word-spacing:18.3px;}
#t36_5{left:353px;top:722px;word-spacing:4.7px;}
#t37_5{left:353px;top:737px;word-spacing:15.7px;}
#t38_5{left:353px;top:752px;word-spacing:17.7px;}
#t39_5{left:353px;top:768px;word-spacing:26.5px;}
#t3a_5{left:353px;top:783px;word-spacing:4px;}
#t3b_5{left:413px;top:783px;}
#t3c_5{left:436px;top:783px;}
#t3d_5{left:333px;top:809px;word-spacing:5.5px;}
#t3e_5{left:353px;top:824px;word-spacing:1.8px;}
#t3f_5{left:353px;top:839px;word-spacing:6.6px;}
#t3g_5{left:353px;top:854px;word-spacing:12.8px;}
#t3h_5{left:552px;top:854px;}
#t3i_5{left:353px;top:869px;}
#t3j_5{left:333px;top:895px;letter-spacing:-0.1px;word-spacing:16.4px;}
#t3k_5{left:353px;top:910px;word-spacing:0.1px;}
#t3l_5{left:353px;top:926px;word-spacing:12.7px;}
#t3m_5{left:353px;top:941px;word-spacing:9.7px;}
#t3n_5{left:353px;top:956px;word-spacing:3.9px;}
#t3o_5{left:463px;top:956px;}
#t3p_5{left:485px;top:956px;}
#t3q_5{left:333px;top:982px;word-spacing:25.5px;}
#t3r_5{left:353px;top:997px;word-spacing:5.7px;}
#t3s_5{left:353px;top:1012px;word-spacing:21.3px;}
#t3t_5{left:353px;top:1027px;word-spacing:5px;}
#t3u_5{left:353px;top:1043px;}
#t3v_5{left:381px;top:1043px;}
#t3w_5{left:399px;top:1043px;}
#t3x_5{left:333px;top:1068px;word-spacing:26.9px;}
#t3y_5{left:353px;top:1083px;word-spacing:6.1px;}
#t3z_5{left:353px;top:1099px;word-spacing:2.7px;}
#t40_5{left:353px;top:1114px;letter-spacing:-0.1px;word-spacing:6.7px;}
#t41_5{left:353px;top:1129px;}
#t42_5{left:381px;top:1129px;}
#t43_5{left:399px;top:1129px;}
#t44_5{left:598px;top:523px;word-spacing:13.6px;}
#t45_5{left:618px;top:539px;word-spacing:1.2px;}
#t46_5{left:618px;top:554px;word-spacing:21.8px;}
#t47_5{left:618px;top:569px;word-spacing:3.8px;}
#t48_5{left:679px;top:569px;}
#t49_5{left:701px;top:569px;}
#t4a_5{left:598px;top:595px;word-spacing:7.2px;}
#t4b_5{left:618px;top:610px;word-spacing:4.3px;}
#t4c_5{left:618px;top:625px;word-spacing:5.4px;}
#t4d_5{left:618px;top:640px;letter-spacing:-0.1px;word-spacing:19.5px;}
#t4e_5{left:618px;top:656px;}
#t4f_5{left:635px;top:656px;}
#t4g_5{left:598px;top:680px;word-spacing:9.4px;}
#t4h_5{left:618px;top:695px;word-spacing:4.6px;}
#t4i_5{left:618px;top:711px;letter-spacing:-0.1px;word-spacing:2.3px;}
#t4j_5{left:618px;top:726px;word-spacing:3.9px;}
#t4k_5{left:762px;top:726px;}
#t4l_5{left:780px;top:726px;}
#t4m_5{left:598px;top:752px;word-spacing:5.6px;}
#t4n_5{left:618px;top:767px;word-spacing:8.1px;}
#t4o_5{left:618px;top:782px;word-spacing:10.8px;}
#t4p_5{left:618px;top:797px;word-spacing:8.8px;}
#t4q_5{left:618px;top:812px;word-spacing:3.9px;}
#t4r_5{left:707px;top:812px;}
#t4s_5{left:729px;top:812px;}
#t4t_5{left:598px;top:838px;letter-spacing:0.4px;word-spacing:18px;}
#t4u_5{left:618px;top:854px;letter-spacing:0.3px;word-spacing:16.4px;}
#t4v_5{left:618px;top:869px;letter-spacing:0.4px;word-spacing:7.1px;}
#t4w_5{left:618px;top:884px;letter-spacing:0.4px;word-spacing:18.6px;}
#t4x_5{left:618px;top:899px;letter-spacing:0.4px;word-spacing:19.2px;}
#t4y_5{left:618px;top:914px;letter-spacing:0.4px;}
#t4z_5{left:642px;top:914px;letter-spacing:0.5px;}
#t50_5{left:598px;top:940px;word-spacing:7.6px;}
#t51_5{left:618px;top:956px;word-spacing:6.8px;}
#t52_5{left:618px;top:971px;word-spacing:17px;}
#t53_5{left:618px;top:986px;word-spacing:16.7px;}
#t54_5{left:618px;top:1001px;word-spacing:3.9px;}
#t55_5{left:744px;top:1001px;}
#t56_5{left:762px;top:1001px;}
#t57_5{left:598px;top:1027px;word-spacing:21.3px;}
#t58_5{left:618px;top:1042px;letter-spacing:0.4px;word-spacing:9.5px;}
#t59_5{left:618px;top:1058px;letter-spacing:0.4px;word-spacing:14.1px;}
#t5a_5{left:618px;top:1073px;letter-spacing:0.4px;word-spacing:12.1px;}
#t5b_5{left:618px;top:1088px;letter-spacing:0.3px;}
#t5c_5{left:636px;top:1088px;letter-spacing:0.4px;}
#t5d_5{left:598px;top:1114px;letter-spacing:0.3px;word-spacing:15.3px;}
#t5e_5{left:618px;top:1129px;letter-spacing:0.4px;word-spacing:5.8px;}
#t5f_5{left:172px;top:36px;word-spacing:4.7px;}
#t5g_5{left:805px;top:36px;}

.s7_5{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFDE-AdvPSA35F5;
	color: rgb(0,0,0);
}

.s3_5{
	FONT-SIZE: 73.1px;
	FONT-FAMILY: BLDFDE-AdvPSA35F5;
	color: rgb(0,0,0);
}

.s6_5{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: BLDFGP-AdvPSA35B5;
	color: rgb(0,0,0);
}

.s4_5{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: BLDFEK-AdvPS_UVCL5;
	color: rgb(0,0,0);
}

.s5_5{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: BLDFJA-AdvOTda3b4f5f-B5;
	color: rgb(0,0,0);
}

.s2_5{
	FONT-SIZE: 40.6px;
	FONT-FAMILY: BLDFEI-AdvPSNCS-R5;
	color: rgb(0,0,0);
}

.s1_5{
	FONT-SIZE: 60.9px;
	FONT-FAMILY: BLDFEI-AdvPSNCS-R5;
	color: rgb(0,0,0);
}

.v1_5{
	-webkit-transform: scale(0.281, 0.25);
	-ms-transform: scale(0.281, 0.25);
	-moz-transform: scale(0.281, 0.25);
	-o-transform: scale(0.281, 0.25);
}

#form5_1{	border-style:none;	z-index:2;	position: absolute;	left:284px;	top:153px;	width:14px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form5_2{	border-style:none;	z-index:2;	position: absolute;	left:326px;	top:98px;	width:14px;	height:17px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}

</style>
<style id="fonts5" type="text/css" >

@font-face {
	font-family: BLDFJA-AdvOTda3b4f5f-B5;
	src: url("5/fonts/BLDFJA-AdvOTda3b4f5f-B.woff") format("woff");
}

@font-face {
	font-family: BLDFEI-AdvPSNCS-R5;
	src: url("5/fonts/BLDFEI-AdvPSNCS-R.woff") format("woff");
}

@font-face {
	font-family: BLDFEK-AdvPS_UVCL5;
	src: url("5/fonts/BLDFEK-AdvPS_UVCL.woff") format("woff");
}

@font-face {
	font-family: BLDFGP-AdvPSA35B5;
	src: url("5/fonts/BLDFGP-AdvPSA35B.woff") format("woff");
}

@font-face {
	font-family: BLDFDE-AdvPSA35F5;
	src: url("5/fonts/BLDFDE-AdvPSA35F.woff") format("woff");
}

</style>
<div id="t1_5" class="t s1_5">approximately 8 nmol/l (231 ng/dl).</div>
<div id="t2_5" class="t v1_5 s2_5">28</div>
<div id="t3_5" class="t s1_5">Indeed, pre-</div>
<div id="t4_5" class="t s1_5">clinical evidence even suggests benefcial eFFects oF</div>
<div id="t5_5" class="t s1_5">higher androgen concentrations on CaP in vitro,</div>
<div id="t6_5" class="t s1_5">resulting in growth inhibition.</div>
<div id="t7_5" class="t v1_5 s2_5">29</div>
<div id="t8_5" class="t s1_5">The current study has several limitations. 1) Our</div>
<div id="t9_5" class="t s1_5">cohort was a relatively small, retrospective sample</div>
<div id="ta_5" class="t s1_5">without a eugonadal comparison group, limiting the</div>
<div id="tb_5" class="t s1_5">generalizability oF our fndings. 2) To our knowledge</div>
<div id="tc_5" class="t s1_5">the eFFects oF TTh on CaP recurrence beyond 3 years</div>
<div id="td_5" class="t s1_5">are unknown and we continue to Follow this cohort</div>
<div id="te_5" class="t s1_5">to determine these eFFects. 3) The absence oF a</div>
<div id="tf_5" class="t s1_5">validated questionnaire on symptom improvement</div>
<div id="tg_5" class="t s1_5">limited our ability to capture the spectrum oF the</div>
<div id="th_5" class="t s1_5">clinical benefts oF TTh. 4) While all patients</div>
<div id="ti_5" class="t s1_5">received RT, the Form oF RT varied among patients,</div>
<div id="tj_5" class="t s1_5">introducing heterogeneity. Although we report a</div>
<div id="tk_5" class="t s1_5">small but statistically signifcant diFFerence in PSA</div>
<div id="tl_5" class="t s1_5">between men who received RT only and those who</div>
<div id="tm_5" class="t s1_5">received RT and ADT, this was not supported by a</div>
<div id="tn_5" class="t s1_5">diFFerence in PSA velocity. It may re±ect the limited</div>
<div id="to_5" class="t s1_5">sample size and the large SD in these subgroups.</div>
<div id="tp_5" class="t s1_5">Despite the data presented in the current and</div>
<div id="tq_5" class="t s1_5">previous studies the lack oF a prospective controlled</div>
<div id="tr_5" class="t s1_5">trial oF TTh in the setting oF CaP limits our ability to</div>
<div id="ts_5" class="t s1_5">declare that TTh is saFe in this population. Patient</div>
<div id="tt_5" class="t s1_5">selection should be diligent and limited to men with</div>
<div id="tu_5" class="t s1_5">quality oF liFe impairment who are at risk For the</div>
<div id="tv_5" class="t s1_5">sequelae oF untreated hypogonadism. ²urther, it is</div>
<div id="tw_5" class="t s1_5">necessary to perForm vigilant monitoring during</div>
<div id="tx_5" class="t s1_5">treatment in these men until more defnitive saFety</div>
<div id="ty_5" class="t s1_5">data are accumulated. Nonetheless, our fndings</div>
<div id="tz_5" class="t s1_5">suggest that TTh is eFFective and potentially saFe in</div>
<div id="t10_5" class="t s1_5">hypogonadal men aFter RT regardless oF primary</div>
<div id="t11_5" class="t s1_5">tumor grade. In conclusion, TTH Following RT For</div>
<div id="t12_5" class="t s1_5">CaP resulted in a minimal mean increase in serum</div>
<div id="t13_5" class="t s1_5">PSA and a low BCR rate.</div>
<div id="t14_5" class="t s3_5">REFERENCES</div>
<div id="t15_5" class="t s4_5">1. Araujo AB, Esche GR, Kupelian V et al: Preva-</div>
<div id="t16_5" class="t s4_5">lence of symptomatic androgen deficiency in</div>
<div id="t17_5" class="t s4_5">men. J Clin Endocrinol Metab 2007;</div>
<div id="t18_5" class="t s5_5">92:</div>
<div id="t19_5" class="t s4_5">4241.</div>
<div id="t1a_5" class="t s4_5">2. Pickles T, Graham P and Members of British</div>
<div id="t1b_5" class="t s4_5">Columbia Cancer Agency Prostate Cohort Out-</div>
<div id="t1c_5" class="t s4_5">comes Initiative: What happens to testosterone</div>
<div id="t1d_5" class="t s4_5">after prostate radiation monotherapy and does it</div>
<div id="t1e_5" class="t s4_5">matter? J Urol 2002;</div>
<div id="t1f_5" class="t s5_5">167:</div>
<div id="t1g_5" class="t s4_5">2448.</div>
<div id="t1h_5" class="t s4_5">3. Morgentaler A: Testosterone and prostate can-</div>
<div id="t1i_5" class="t s4_5">cer: an historical perspective on a modern myth.</div>
<div id="t1j_5" class="t s4_5">Eur Urol 2006;</div>
<div id="t1k_5" class="t s5_5">50:</div>
<div id="t1l_5" class="t s4_5">935.</div>
<div id="t1m_5" class="t s4_5">4. Kaufman JM and Graydon RJ: Androgen</div>
<div id="t1n_5" class="t s4_5">replacement after curative radical prostatectomy</div>
<div id="t1o_5" class="t s4_5">for prostate cancer in hypogonadal men. J Urol</div>
<div id="t1p_5" class="t s4_5">2004;</div>
<div id="t1q_5" class="t s5_5">172:</div>
<div id="t1r_5" class="t s4_5">920.</div>
<div id="t1s_5" class="t s4_5">5. Agarwal PK and Oefelein MG: Testosterone</div>
<div id="t1t_5" class="t s4_5">replacement therapy after primary treatment for</div>
<div id="t1u_5" class="t s4_5">prostate cancer. J Urol 2005;</div>
<div id="t1v_5" class="t s5_5">173:</div>
<div id="t1w_5" class="t s4_5">533.</div>
<div id="t1x_5" class="t s4_5">6. Pastuszak AW, Pearlman AM, Lai WS et al:</div>
<div id="t1y_5" class="t s4_5">Testosterone replacement therapy in patients</div>
<div id="t1z_5" class="t s4_5">with prostate cancer after radical prostatectomy.</div>
<div id="t20_5" class="t s4_5">J Urol 2013;</div>
<div id="t21_5" class="t s5_5">190:</div>
<div id="t22_5" class="t s4_5">639.</div>
<div id="t23_5" class="t s4_5">7. Khera M, Grober ED, Najari B et al: Testosterone</div>
<div id="t24_5" class="t s4_5">replacement therapy following radical prosta-</div>
<div id="t25_5" class="t s4_5">tectomy. J Sex Med 2009;</div>
<div id="t26_5" class="t s5_5">6:</div>
<div id="t27_5" class="t s4_5">1165.</div>
<div id="t28_5" class="t s4_5">8. Pastuszak AW, Pearlman AM, Godoy G et al:</div>
<div id="t29_5" class="t s4_5">Testosterone replacement therapy in the setting</div>
<div id="t2a_5" class="t s4_5">of prostate cancer treated with radiation. Int J</div>
<div id="t2b_5" class="t s4_5">Impot Res 2013;</div>
<div id="t2c_5" class="t s5_5">25:</div>
<div id="t2d_5" class="t s4_5">24.</div>
<div id="t2e_5" class="t s4_5">9. Balbontin FG, Moreno SA, Bley E et al: Long-</div>
<div id="t2f_5" class="t s4_5">acting testosterone injections for treatment of</div>
<div id="t2g_5" class="t s4_5">testosterone deficiency after brachytherapy for</div>
<div id="t2h_5" class="t s4_5">prostate cancer. BJU Int 2014;</div>
<div id="t2i_5" class="t s5_5">114:</div>
<div id="t2j_5" class="t s4_5">125.</div>
<div id="t2k_5" class="t s4_5">10. Morales A, Black AM and Emerson LE: Testos-</div>
<div id="t2l_5" class="t s4_5">terone administration to men with testosterone</div>
<div id="t2m_5" class="t s4_5">deficiency syndrome after external beam radio-</div>
<div id="t2n_5" class="t s4_5">therapy for localized prostate cancer: preliminary</div>
<div id="t2o_5" class="t s4_5">observations. BJU Int 2009;</div>
<div id="t2p_5" class="t s5_5">103:</div>
<div id="t2q_5" class="t s4_5">62.</div>
<div id="t2r_5" class="t s4_5">11. Sarosdy MF: Testosterone replacement for</div>
<div id="t2s_5" class="t s4_5">hypogonadism after treatment of early prostate</div>
<div id="t2t_5" class="t s4_5">cancer</div>
<div id="t2u_5" class="t s4_5">with</div>
<div id="t2v_5" class="t s4_5">brachytherapy.</div>
<div id="t2w_5" class="t s4_5">Cancer</div>
<div id="t2x_5" class="t s4_5">2007;</div>
<div id="t2y_5" class="t s5_5">109:</div>
<div id="t2z_5" class="t s4_5">536.</div>
<div id="t30_5" class="t s4_5">12. Morgentaler A, Lipshultz LI, Bennett R et al:</div>
<div id="t31_5" class="t s4_5">Testosterone therapy in men with untreated</div>
<div id="t32_5" class="t s4_5">prostate cancer. J Urol 2011;</div>
<div id="t33_5" class="t s5_5">185:</div>
<div id="t34_5" class="t s4_5">1256.</div>
<div id="t35_5" class="t s4_5">13. Horwitz EM, Thames HD, Kuban DA et al:</div>
<div id="t36_5" class="t s4_5">Definitions of biochemical failure that best pre-</div>
<div id="t37_5" class="t s4_5">dict clinical failure in patients with prostate</div>
<div id="t38_5" class="t s4_5">cancer treated with external beam radiation</div>
<div id="t39_5" class="t s4_5">alone: a multi-institutional pooled analysis.</div>
<div id="t3a_5" class="t s4_5">J Urol 2005;</div>
<div id="t3b_5" class="t s5_5">173:</div>
<div id="t3c_5" class="t s4_5">797.</div>
<div id="t3d_5" class="t s4_5">14. Marks LS, Mazer NA, Mostaghel E et al: Effect</div>
<div id="t3e_5" class="t s4_5">of testosterone replacement therapy on prostate</div>
<div id="t3f_5" class="t s4_5">tissue in men with late-onset hypogonadism: a</div>
<div id="t3g_5" class="t s4_5">randomized controlled trial. JAMA 2006;</div>
<div id="t3h_5" class="t s5_5">296:</div>
<div id="t3i_5" class="t s4_5">2351.</div>
<div id="t3j_5" class="t s4_5">15. Rhoden EL and Morgentaler A: Testosterone</div>
<div id="t3k_5" class="t s4_5">replacement therapy in hypogonadal men at high</div>
<div id="t3l_5" class="t s4_5">risk for prostate cancer: results of 1 year of</div>
<div id="t3m_5" class="t s4_5">treatment in men with prostatic intraepithelial</div>
<div id="t3n_5" class="t s4_5">neoplasia. J Urol 2003;</div>
<div id="t3o_5" class="t s5_5">170:</div>
<div id="t3p_5" class="t s4_5">2348.</div>
<div id="t3q_5" class="t s4_5">16. Menon M, Bhandari M, Gupta N et al:</div>
<div id="t3r_5" class="t s4_5">Biochemical recurrence following robot-assisted</div>
<div id="t3s_5" class="t s4_5">radical prostatectomy: analysis of 1384 pa-</div>
<div id="t3t_5" class="t s4_5">tients with a median 5-year follow-up. Eur Urol</div>
<div id="t3u_5" class="t s4_5">2010;</div>
<div id="t3v_5" class="t s5_5">58:</div>
<div id="t3w_5" class="t s4_5">838.</div>
<div id="t3x_5" class="t s4_5">17. Pollack A, Hanlon AL, Movsas B et al:</div>
<div id="t3y_5" class="t s4_5">Biochemical failure as a determinant of distant</div>
<div id="t3z_5" class="t s4_5">metastasis and death in prostate cancer treated</div>
<div id="t40_5" class="t s4_5">with radiotherapy. Int J Radiat Oncol Biol Phys</div>
<div id="t41_5" class="t s4_5">2003;</div>
<div id="t42_5" class="t s5_5">57:</div>
<div id="t43_5" class="t s4_5">19.</div>
<div id="t44_5" class="t s4_5">18. Shipley WU, Thames HD, Sandler HM et al:</div>
<div id="t45_5" class="t s4_5">Radiation therapy for clinically localized prostate</div>
<div id="t46_5" class="t s4_5">cancer: a multi-institutional pooled analysis.</div>
<div id="t47_5" class="t s4_5">JAMA 1999;</div>
<div id="t48_5" class="t s5_5">281:</div>
<div id="t49_5" class="t s4_5">1598.</div>
<div id="t4a_5" class="t s4_5">19. Zelefsky MJ, Leibel SA, Gaudin PB et al: Dose</div>
<div id="t4b_5" class="t s4_5">escalation with three-dimensional conformal ra-</div>
<div id="t4c_5" class="t s4_5">diation therapy affects the outcome in prostate</div>
<div id="t4d_5" class="t s4_5">cancer. Int J Radiat Oncol Biol Phys 1998;</div>
<div id="t4e_5" class="t s5_5">41:</div>
<div id="t4f_5" class="t s4_5">491.</div>
<div id="t4g_5" class="t s4_5">20. Fukunaga-Johnson N, Sandler HM, McLaughlin</div>
<div id="t4h_5" class="t s4_5">PW et al: Results of 3D conformal radiotherapy</div>
<div id="t4i_5" class="t s4_5">in the treatment of localized prostate cancer. Int</div>
<div id="t4j_5" class="t s4_5">J Radiat Oncol Biol Phys 1997;</div>
<div id="t4k_5" class="t s5_5">38:</div>
<div id="t4l_5" class="t s4_5">311.</div>
<div id="t4m_5" class="t s4_5">21. Huggins C and Hodges CV: Studies on prostatic</div>
<div id="t4n_5" class="t s4_5">cancer: I. The effect of castration, of estrogen</div>
<div id="t4o_5" class="t s4_5">and of androgen injection on serum phospha-</div>
<div id="t4p_5" class="t s4_5">tases in metastatic carcinoma of the prostate.</div>
<div id="t4q_5" class="t s4_5">1941. J Urol 2002;</div>
<div id="t4r_5" class="t s5_5">168:</div>
<div id="t4s_5" class="t s4_5">9.</div>
<div id="t4t_5" class="t s4_5">22. Endogenous Hormones and Prostate Cancer</div>
<div id="t4u_5" class="t s4_5">Collaborative Group, Roddam AW, Allen NE</div>
<div id="t4v_5" class="t s4_5">et al: Endogenous sex hormones and prostate</div>
<div id="t4w_5" class="t s4_5">cancer: a collaborative analysis of 18 pro-</div>
<div id="t4x_5" class="t s4_5">spective studies. J Natl Cancer Inst 2008;</div>
<div id="t4y_5" class="t s5_5">100:</div>
<div id="t4z_5" class="t s4_5">170.</div>
<div id="t50_5" class="t s4_5">23. Muller RL, Gerber L, Moreira DM et al: Serum</div>
<div id="t51_5" class="t s4_5">testosterone and dihydrotestosterone and pros-</div>
<div id="t52_5" class="t s4_5">tate cancer risk in the placebo arm of the</div>
<div id="t53_5" class="t s4_5">Reduction by Dutasteride of Prostate Cancer</div>
<div id="t54_5" class="t s4_5">Events trial. Eur Urol 2012;</div>
<div id="t55_5" class="t s5_5">62:</div>
<div id="t56_5" class="t s4_5">757.</div>
<div id="t57_5" class="t s4_5">24. Cui Y, Zong H, Yan H et al: The effect</div>
<div id="t58_5" class="t s4_5">of testosterone replacement therapy on pros-</div>
<div id="t59_5" class="t s4_5">tate cancer: a systematic review and meta-</div>
<div id="t5a_5" class="t s4_5">analysis. Prostate Cancer Prostatic Dis 2014;</div>
<div id="t5b_5" class="t s5_5">17:</div>
<div id="t5c_5" class="t s4_5">132.</div>
<div id="t5d_5" class="t s4_5">25. Morgentaler A and Traish AM: Shifting the</div>
<div id="t5e_5" class="t s4_5">paradigm of testosterone and prostate cancer:</div>
<div id="t5f_5" class="t s6_5">TESTOSTERONE THERAPY AFTER RADIATION THERAPY FOR PROSTATE CANCER</div>
<div id="t5g_5" class="t s7_5">1275</div>

<form>
<input type="button"  tabindex="2"  id="form5_1" name="62 0 R"  pdfFieldName="62 0 R" onclick="window.location.href='6.html';" style="cursor:pointer;"  title="Page 6" />
<input type="button"  tabindex="1"  id="form5_2" name="61 0 R"  pdfFieldName="61 0 R" onclick="window.location.href='6.html';" style="cursor:pointer;"  title="Page 6" />

</form>
<div id="pg5Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg5"><object width="893" height="1196" data="5/5.svg" type="image/svg+xml" id="pdf5" style="width:893px; height:1196px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!--[if lt IE 9]><script type="text/javascript">
var divCount = 197;
for (var i = 1; i < divCount; i++) {
    var div = document.getElementById("t" + i.toString(36) + "_5");
    if (div !== null) {
        div.style.top = (div.offsetTop * 4) + "px";
        div.style.left = (div.offsetLeft * 4) + "px";
        div.style.zoom = "25%";
    }
}
</script><![endif]-->

</div>
